UPDATE: Unilabs Offering Genomic Health's Oncotype DX Breast Cancer Test in UK | GenomeWeb

The story has been updated to clarify that the Oncotype DX breast cancer test will be conducted at Genomic Health's laboratory in California.

NEW YORK (GenomeWeb News) – Swiss-based diagnostics firm Unilabs said today that it is now offering Genomic Health's Oncotype DX breast cancer test at partner clinics and hospitals.

As part of its agreement with Genomic Health, physicians can send their patients' tissue samples to the Unilabs HIS laboratory. All tests will be sent to Genomic Health's centralized laboratory where the Oncotype DX testing will be done.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.

At Nature, John Wilbanks and Eric Topol call for openness in health data.

Law.com predicts that genomic and genetic testing will become common in toxic tort cases.

A Pew Research Center report finds that most Americans are wary of using technologies like gene editing to enhance human abilities.